N-Nitroso-N-methylurea (NMU;MNU;NMH) is a potent carcinogen, mutagen and teratogenand. N-Nitroso-N-methylurea is a direct-acting alkylating agent that interacts with DNA. N-Nitroso-N-methylurea targets multiple animal organs to cause various cancer and/or degenerative disease. N-Nitroso-N-methylurea is also a precursor in the synthesis of diazomethane.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

1-甲基-1-亚硝基脲；N-亚硝基-N-甲基脲；NMU；MNU；NMH

DMSO : 125 mg/mL (1212.65 mM; Need ultrasonic)

N-Nitroso-N-methylurea (NMU; 5 μM) treatment increases the cellular NF-κB activity in human malignant keratinocytes. N-Nitroso-N-methylurea also increases the amount of I-κBα phosphorylation.

N-Nitroso-N-methylurea (NMU) gives intravenously to rats at age 50 days induced mammary carcinomas in 89% of BUF/N, 73% of Sprague-Dawley, and 89% of F344 females. Latent periods are, respectively, 77, 86, and 94 days. Doubling times of NMU-induced primary and transplanted carcinomas are similar to 7 days. Cachexia ensues at the 5th week from the onset of the first tumor. When the tumor is larger than 15 g, hypercalcemia is usually observed.